相关实验视频
Updated: Jun 17, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
在儿科无氧性皮肤炎中使用口服Janus激酶抑制剂
Elsy M Navarrete-Rodríguez1, Désirée Larenas-Linnemann2,3, Helena Vidaurri de la Cruz4
1Allergy and Immunology Department, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.
简氏激酶抑制剂 (JAKi) 有效治疗中度至重度的青少年皮炎 (AD) 迅速发病. 虽然通常是安全的,但疹和是儿童患者监测的潜在副作用.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 青少年中度至重度的亚托皮炎 (AD) 通常需要全身治疗.
- 雅努斯激酶抑制剂 (JAKi) 对成人阿尔茨海默病有效,但儿科数据有限.
- 了解JAKi在儿科阿尔茨海默病的疗效和安全性对于治疗选择至关重要.
研究的目的:
- 分析Janus激酶抑制剂 (JAKi) 在治疗儿科亚型皮肤炎 (AD) 中的疗效和安全性.
- 为了比较不同JAK抑制剂在患有中度至重度AD的青少年中的有效性.
- 为了确定与JAKi在儿科阿尔茨海默病患者中的使用相关的潜在不良事件.
主要方法:
- 对儿童AD中JAK抑制剂的临床试验和研究的系统综述.
- 对疗效数据的分析,包括作用的开始和症状的减少.
- 评估安全概况,包括常见和严重的不良事件.
主要成果:
- 阿布罗西提尼布,巴里西提尼布和乌帕达西提尼布在患有中度至重度阿尔茨海默病的青少年中显示出有效性,作用迅速开始.
- 巴里西提尼布在2-10岁的儿童中没有效果,患有中度至严重的AD.
- 试验中没有记录主要的安全问题;注意到疹和,但可以管理.
结论:
- 雅克抑制剂对于中度至重度AD的青少年来说是一个有效的全身治疗选择.
- 临床医生可以根据患者的需求和临床特征选择JAK抑制剂.
- 未来的研究和新疗法将进一步完善JAKi在不同患者阶段管理AD方面的作用.
更多相关视频
09:32Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
相关概念视频
The JAK-STAT Signaling Pathway
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...